Axogen, Inc. (AXGN) Earnings Call Analysis

NASDAQ · Healthcare · Medical Devices

Earnings Reports

• Axogen (AXGN) Q2 2026: Breast Segment Drives 47% Growth, Reshaping Margin Mix
  July 29, 2026
• Axogen (AXGN) Q1 2026: Coverage Expands to 86%, Unlocking New Nerve Repair Adoption
  April 28, 2026
• Axogen (AXGN) Q4 2025: Avance BLA Approval Unlocks 12-Year Exclusivity, Elevates Margin Pathway
  February 25, 2026
• Axogen (AXGN) Q3 2025: Nerve Repair Revenue Jumps 23.5% as BLA Milestone Nears
  October 29, 2025
• Axogen (AXGN) Q2 2025: High-Potential Account Productivity Up 21%, Fueling Durable Nerve Care Growth
  August 05, 2025
• Axogen (AXGN) Q1 2025: High-Potential Account Productivity Up 24%, Accelerating Standard of Care Push
  July 06, 2025
• Axogen (AXGN) Q3 2024: 18% Revenue Growth Signals Execution Strength as BLA Milestone Sets Up 12-Year Exclusivity Path
  November 07, 2024
• Axogen (AXGN) Q2 2024: Core Accounts Hit 412 as Nerve Repair Penetration Accelerates
  August 08, 2024
• Axogen (AXGN) Q1 2024: Core Accounts Drive 13% Growth as Nerve Protection Portfolio Expands
  May 02, 2024
• Axogen (AXGN) Q4 2023: Scheduled Procedures Surge 25%, Core Account Penetration Deepens
  March 05, 2024

Browse all companies